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ABSTRACT 
Despite being amongst the most characterized G protein-coupled receptors (GPCRs), adenosine 
receptors (ARs) have always been a difficult target in drug design. To date, no agonist other than 
the natural effector and the diagnostic regadenoson has been approved for human use. Recently, 
the structure of the adenosine A1 receptor (A1R) was determined in the active, Gi protein 
complexed state; this has important repercussions for structure-based drug design. Here, we 
employed supervised molecular dynamics simulations and mutagenesis experiments to extend 
the structural knowledge of the binding of selective agonists to A1R. Our results identify new 
residues involved in the association and dissociation pathway, suggest the binding mode of N6-
cyclopentyladenosine (CPA) related ligands, and highlight the dramatic effect that chemical 
modifications can have on the overall binding mechanism. 
1 Introduction 
The dephosphorylation of adenosine triphosphate (ATP), diphosphate (ADP), and 
monophosphate (AMP) produces adenosine1, a nucleoside present in extracellular concentrations 
of 20-300 nM under physiological conditions2. Adenosine acts ubiquitously on four different G 
protein-coupled receptors (GPCRs), the adenosine receptor 1 (A1R), 2A (A2AR), 2B (A2BR) and 
3 (A3R) contributing to the broad range of purinergic signalling
3,4. The main effect mediated by 
adenosine comprises of the inhibition or stimulation of adenylate cyclase, the activation of 
phospholipase C, intracellular Ca2+ regulation, and the mitogen-activated protein kinases 
(MAPK) pathways5.  
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 3
 Agonist-activated A1R couples to inhibitory G proteins (Gi/o) to trigger numerous 
physiological effects. For example, it produces negative chronotropic and inotropic effects in the 
heart6, reduces the neuronal firing rate by blocking neurotransmitter release in the central 
nervous system (CNS), and inhibits lipolysis and renin release7. Therapeutic approaches based 
on stimulating the A1R could pave the way for hitherto unavailable tools to treat the central 
nervous system (CNS) and cardiovascular diseases5,8. From this standpoint, the structure-based 
drug design (SBDD) of novel agonists can exploit the recent cryo-EM structure of A1R in 
complex with both Gi2 and adenosine
9. Like all the other GPCRs, A1R presents a transmembrane 
domain (TMD) formed by seven α-helixes spanning the cytosolic membrane and shaping the 
orthosteric and the intracellular Gi protein binding sites (Figure S1a). Three intracellular loops 
(ICL1-3) and three extracellular loops (ECL1-3) interconnect the TM helices. ECL2, the longest 
A1R loop, orients almost perpendicularly to the plane of the membrane both in the active
9 and 
inactive10,11 A1R states, in contrast to ECL2 of A2AR, which is almost parallel to the membrane
10. 
ECL2 is important for A1R ligands
12; it has been implicated in the intermediate states that 
anticipate the orthosteric complex, therefore acting as a selectivity filter. Moreover, positive 
allosteric modulators can to bind to it13,14.  
 The key orthosteric interactions between adenosine and A1R (Figure S1b) are hydrogen 
bonds with residues N2546.55, S2777.42, H2787.43, and a π-π interaction that involves F171ECL2. 
AR agonists bearing small N6-cycloalkyl groups, like the N6-cyclopentyladenosine (CPA, 
Figure 1), display A1R selectivity
15. It is proposed that the ligand selectivity for A1R is driven by 
a small hydrophobic pocket underneath ECL3, due to the presence of T2707.35 in place of 
M2707.35 (A2A)
16,9,10.  
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  Here, we extensively studied the A1R recognition of adenosine, 5’-N-
carboxamidoadenosine (NECA), CPA, and the recently characterized agonists HOCPA and 
BnOCPA17 (Figure 1). Binding and unbinding pathways were simulated by means of supervised 
molecular dynamics (SuMD)18,19 and the outcomes tested in mutagenesis experiments to identify 
A1R residues involved along the route towards and from the orthosteric site. We propose the 
binding conformation of N6-cyclopenthyl agonists, and how chemical modifications could 
impact the binding mechanisms of these selective A1R agonists. Our results can be framed within 
the dynamic nature of ligand-receptor complex formations and highlight the dramatic effect on 
drug binding kinetics triggered by chemical substitutions. 
 
Figure 1. A1R agonists considered. Adenosine is the endogenous effector; NECA is a nonselective 
exogenous ARs agonist; CPA represent a prototypical A1R selective agonist; HOCPA and BnOCPA are 
A1R selective analogues of CPA. 
 
2 Methods 
2.1 Experimental Methods 
2.1.1 Compounds 
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Adenosine, NECA ((2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-
carboxamide), CPA, were purchased from Sigma-Aldrich and dissolved in dimethyl-sulphoxide 
(DMSO). HOCPA and BnOCPA was synthesised as described in Knight et al., 2016 (compounds 
6 and 7 respectfully). CA200645, a high affinity AR xanthine amine congener (XAC) derivative 
containing a polyamide linker connected to the BY630 fluorophore, was purchased from 
HelloBio (Bristol, UK) and dissolved in DMSO. The concentration of DMSO was maintained to 
1.1% for NanoBRET ligand-binding experiments using CA200645. 
2.1.2 Generation of mutant A1R constructs 
The NanoLluc(Nluc)-tagged human A1R pcDNA3.1+ construct used to generate stable HEK 
293 cell lines was kindly gifted to us by Stephen Hill and Stephen Briddon (University of 
Nottingham). Mutations within the A1R were made using the QuikChange Lightening Site-
Directed Mutagenesis Kit (Agilent Technologies) in accordance with the manufacturer’s 
instructions. All oligonucleotides used for mutagenesis were designed using the online Agilent 
Genomics ‘QuikChange Primer Design’ tool and purchased from Merck. All constructs were 
confirmed by in-house Sanger sequencing. 
2.1.3 Cell culture and transfection’s 
HEK 293 cells in a single well of 6-well plate (confluency ≥ 80%) were transfected with 2 μg 
of DNA using polyethyleneimine (PEI, 1 mg/ml, MW = 25,000 g/mol) (Polysciences Inc) at a 
DNA:PEI ratio of 1:6 (w/v). Briefly, DNA and PEI were added to separate sterile tubes 
containing 150 mM sodium chloride (NaCl) (total volume 50 μl), allowed to incubate at room 
temperature for 5 minutes, mixing together and incubating for a further 10 minutes prior to 
adding the combined mix dropwise to the cells. 48 hours post-transfection, stable Nluc-A1R 
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 6
expressing HEK 293 cells were selected using 600 μg/mL Geneticin (Thermo Fisher Scientific) 
whereby the media was changed every two days. HEK 293 cell lines were routinely cultured in 
DMEM/F-12 GlutaMAX (Thermo Fisher Scientific) supplemented with 10% FBS (F9665, 
Sigma-Aldrich). 
2.1.4 Analysis of A1R cell-surface expression using flow cytometry 
HEK 293 cells and WT or mutant A1R expressing HEK 293 cells were harvested using a non-
enzymatic cell dissociation solution (Sigma-Aldrich) and washed with PBS prior to counting. 0.5 
x 106 cells were washed three times in flow buffer (PBS supplemented with 1% BSA and 0.03% 
sodium azide) before re-suspending in 50 μl flow buffer containing anti-Nluc polyclonal primary 
antibody raised in rabbit (Kindly gifted by Promega) at 1:100 dilution and incubated at room 
temperature for 1 hour. All samples were washed three times with flow buffer and re-suspended 
in 50 μl flow buffer containing Allophycocyanin (APC)-conjugated anti-Rabbit IgG (Thermo 
Fisher Scientific, 31984) at 1:150 dilution and incubated for 1 hour at room temperature in the 
dark. The cells received a final three washes and were re-suspended in 300 μl flow buffer.  
Analysis was conducted using a BD AccuriTM C6 Plus Flow Cytometer which is equipped 
with a blue (488 nm) and red (640 nm) laser, two light scatter detectors (FSC and SCC) and four 
fluorescence detectors (FL1 Em. λ 530/30 nm, FL2 Em. λ 585/40 nm, FL3 Em. λ 570 and FL4 
Em. λ 675/25 nm). FL4 optical filters were chosen APC (Ex. λ 633 nm and Em. λ 660 nn). 
Unstained cells and HEK 293 cells without A1R expression were used as controls for 
autofluorescence and unspecific antibody binding, respectively. All data is collected by the flow 
cytometer and analysis can be conducted at any time using the BD AccuriTM C6 software. The 
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images for figures were made in FlowJo® (V7.6.5), an analysis platform for single-cell flow 
cytometry analysis.  
2.1.5 BRET assays for binding 
Saturation binding at WT and mutant A1R for the determination of CA200645 KD was 
conducted using NanoBRET. The Nluc acts as the BRET donor (luciferase oxidizing its 
substrate, furimazine) and CA200645 acted as the fluorescent acceptor. Here, HEK 293 cells 
stably expressing WT or mutant Nluc-A1R 24 hours post plating (10,000 cells/well of a 96-well 
plate) where pre-treated with 0.1 µM furimazine for 5 minutes prior to stimulated with 
CA200645 at a range of concentrations (0 to 300 nM). Following a 30 minute incubation period 
at room temperature, filtered light emission at 450 nm and > 610 nm (640-685 nm band pass 
filter) was measured using a Mithras LB 940 and the raw BRET ratio calculated (610 nm/450 
nm). Non-specific binding was determined by saturating concentrations of DPCPX (1 µM) and 
subtracted from the BRET ratio. BRET ratio data was then fit to the ‘One site – Specific binding’ 
model built into Prism. 
As described previously (Barkan et al. 2019), NanoBRET competition binding assays were 
conducted to determine the affinity (pKi) of various A1R compounds. Briefly, following a 5 
minute pre-incubation with 0.1 µM furimazine, cells were co-stimulated with CA200645 (used at 
25 nM, as previously reported (Stoddart et al. 2015; Barkan et al. 2019)) and increasing 
concentration of unlabeled ligand and emission at 450 nm and > 610 nm immediately measured. 
The BRET ratio at 10 minutes post stimulation was fitted with the ‘one-site – Ki model’ derived 
from the Cheng and Prusoff correction (Chen and Prusoff, 1973), built into Prism to determine 
affinity (pKi) values for all unlabeled agonists at the A1Rs. The determined Kd of CA200645 at 
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the mutant A1R was taken into account during analysis. Nonspecific binding was determined 
using a high concentration of unlabelled antagonist, at 1 µM DPCPX.  
2.1.6 Data analysis 
All experiments were conducted in duplicate (technical replicates) to ensure the reliability of 
single values. Statistical analysis, performed using Prism 8.0, was undertaken for experiments 
where the group size was at least n = 3 and these independent values used to calculate statistical 
significance (*, p< 0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001) using a one-way ANOVA 
with a Dunnett’s post-test for multiple comparisons.  
2.2 Computational Methods 
2.2.1 Biological targets and ligands force field parameters 
All ten systems (Table 1) were prepared for molecular dynamics (MD) simulations using the 
CHARMM3620,21/CGenFF 3.0.122–24 force field combination. Initial ligand force filed topology 
and parameter files were obtained from the ParamChem webserver22. Adenosine and NECA are 
already well-parameterized in the CGenFF force filed. Optimized parameters for HOCPA and 
BnOCPA from our previous work25 were used and transferred to CPA. 
2.2.2 Protein preparation 
The active A1R structure (Table 1) was retrieved from the Protein Data Bank
26 (PDB code 
6D9H9). For SuMD binding simulations, the agonists were placed at least 30 Å from the binding 
site in five different systems. For SuMD unbinding, the experimental coordinates (PDB 6D9H) 
were used to simulate the adenosine, while representative frames (ligand orthosteric 
conformations close to the experimental bound adenosine on A1R) from the SuMD binding were 
used to start the SuMD unbinding of NECA, CPA, HOCPA and BnOCPA. The A1R intracellular 
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loop 3 (ICL3) was modelled using Modeller 9.1927. For all the 10 systems (Table 1), hydrogen 
atoms were added by means of the pdb2pqr28 and propka29 software (considering a simulated pH 
of 7.0); the protonation of titratable side chains was checked by visual inspection. The resulting 
receptor was inserted in a square 90 Å x 90 Å 1-palmitoyl-2-oleyl-sn-glycerol-3-phosphocholine 
(POPC) bilayer (previously built by using the VMD Membrane Builder plugin 1.1, Membrane 
Plugin, Version 1.1 at: http://www.ks.uiuc.edu/Research/vmd/plugins/membrane/), through an 
insertion method30. The receptor orientation was obtained by superposing the coordinates on the 
corresponding structure retrieved from the OPM database31. Lipids overlapping the receptor 
transmembrane helical bundle were removed and TIP3P water molecules32 were added to the 
simulation box by means of the VMD Solvate plugin 1.5 (Solvate Plugin, Version 1.5. at 
<http://www.ks.uiuc.edu/Research/vmd/plugins/solvate/). Finally, overall charge neutrality was 
reached by adding Na+/Cl- counter ions up to the final concentration of 0.150 M), using the 
VMD Autoionize plugin 1.3 (Autoionize Plugin, Version 1.3. at 
<http://www.ks.uiuc.edu/Research/vmd/plugins/autoionize/).  
2.2.3 Systems equilibration and general MD settings 
The MD engine ACEMD33 was employed for both the equilibration and productive 
simulations. The equilibration of the membrane systems was achieved in isothermal-isobaric 
conditions (NPT) using the Berendsen barostat34 (target pressure 1 atm) and the Langevin 
thermostat35 (target temperature 300 K) with low damping of 1 ps-1. A four-stage procedure was 
performed (integration time step of 2 fs): first, clashes between protein and lipid atoms were 
reduced through 2000 conjugate-gradient minimization steps, then a 2 ns long MD simulation 
was run with a positional constraint of 1 kcal mol-1 Å-2 on protein and lipid phosphorus atoms. 
During the second stage, 20 ns of MD simulation were performed constraining only the protein 
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atoms, while in the last equilibration stage, positional constraints were applied only to the protein 
backbone alpha carbons, for a further 20 ns. Globular protein equilibration was achieved in two 
steps: after 500 cycles of conjugate-gradient minimization, the system was simulated for 5 ns, 
employing an integration time step of 2 fs, in the isothermal-isobaric conditions (NPT). 
Productive trajectories (Table S4) were computed with an integration time step of 4 fs in the 
canonical ensemble (NVT). The target temperature was set at 300 K, using a thermostat damping 
of 0.1 ps-1; the M-SHAKE algorithm36,37 was employed to constrain the bond lengths involving 
hydrogen atoms. The cut-off distance for electrostatic interactions was set at 9 Å, with a 
switching function applied beyond 7.5 Å. Long-range Coulomb interactions were handled using 
the particle mesh Ewald summation method (PME)38 by setting the mesh spacing to 1.0 Å. 
2.2.4 The supervised MD (SuMD) protocol.  
The supervised molecular dynamics (SuMD) is an adaptive sampling method39 for speeding up 
the simulation of binding18,40 and unbinding processes19,41. In the simplest SuMD 
implementation, sampling is gained without the introduction of any energetic bias, by applying a 
tabu–like algorithm to monitor the distance between the centers of mass (or the geometrical 
centers) of the ligand and the predicted binding site or the receptor. However, the supervision of 
a second metric of the system can be considered41. A series of short unbiased MD simulations 
are performed, and after each simulation, the distances (collected at regular time intervals) are 
fitted to a linear function. If the resulting slope is negative (for binding) or positive (for 
unbinding) the next simulation step starts from the last set of coordinates and velocities 
produced, otherwise, the simulation is restarted by randomly assigning the atomic velocities.  
2.2.5 Settings for SuMD binding to the A1R. 
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To simulate the agonists’ binding to the A1R (Table 1, Video S1-S5) the distance between the 
centroid of the ligand and the centroid of the orthosteric residues N2546.55, F171ECL2, T2777.42, 
and H2787.43 was supervised during 500 ns long time windows until it reached a value less than 4 
Å. Then? 
2.2.6 Settings for SuMD unbinding from the A1R. 
For the SuMD unbinding (Table 1, Video S1-S4), differently from the SuMD binding 
algorithm, the length (Δt) of the short simulations increases along the dissociation pathway, 
according to the formula: 
∆  ∆   (1) 
Δt0 is the duration of the very first MD time window and Nti is a factor that is picked from 
three user-defined values (Nt1, Nt2, and Nt3), according to the last ligand-protein distance 
detected. At the end of each MD run, the ligand-protein distance (rL) is compared to three 
distance threshold values (D1, D2 and D3, also defined by the user), allowing a decision on the 
value of Nti factor according to the following conditions: 
      	     1 (2) 
         	      (3) 
         	      (4) 
      	       (5) 
Values of 3 Å, 5 Å and 8 Å were used for D1, D2 and D3 respectively, while Nt1, Nt2, and Nt3 
were set to 2, 4, and 8 (SuMD time windows of 100 ps, 200 ps, 400 ps and 800 ps). 
The adenosine SuMD binding and unbinding trajectories were the same as our previous work19. 
2.2.7 SuMD path sampling protocol 
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Further MD sampling (SuMD path sampling, Table 1) was performed using the outputs from 
each SuMD replica (Video S1-S4) for both binding and unbinding. Each trajectory was aligned 
on the protein alpha carbon atoms and the frames were clustered according to the ligand root 
mean square deviation (RMSD) to the starting positions (bin of 1 Å). A frame from each group 
was randomly extracted and used as a starting point for 20 ns long classic MD simulations. 
2.2.8 Analysis of the MD trajectories 
Only the MD trajectories from the SuMD path sampling were analyzed. Interatomic contacts 
and root mean square deviations (RMSD) were computed using VMD42. Contacts were 
considered productive if the distance between two atoms was less than 3.5 Å. Ligand-protein 
hydrogen bonds were detected using the GetContacts scripts tool (https://getcontacts.github.io), 
setting a hydrogen bond donor-acceptor distance of 3.3 Å and an angle value of 150° as 
geometrical cut-offs. Contacts and hydrogen bond persistency are quantified as the percentage of 
frames (considering all the frames obtained by merging the different replicas) in which protein 
residues formed contacts or hydrogen bonds with the ligand. The computation takes into account 
direct and water-mediated interactions.  
Distances between atoms were computed using PLUMED 2.343. The molecular mechanics 
generalized Born surface area (MM/GBSA) energy was computed with the MMPBSA.py44 script 
(AmberTools17 suite at http://ambermd.org/), after transforming the CHARMM psf topology 
files to an Amber prmtop format using ParmEd (documentation. at 
<http://parmed.github.io/ParmEd/html/index.html). We preferred the MM/GBSA approach over 
the molecular Poisson-Boltzmann surface area (MM/PBSA) because binding and unbinding 
paths are not compatible with a grid method45.  
2.3 Numbering system 
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Throughout the manuscript, the Ballesteros-Weinstein residues numbering system for the 
GPCRs46 is adopted as superscript. 
 
Table 1. The ten systems simulated employing SuMD and SuMD path sampling. 
Ligand Transition # SuMD 
replicas 
Total 
SuMD path 
sampling 
Adenosine Binding 9 5.18 μs 
Unbinding 5 3.09 μs 
NECA Binding 6 1.86 μs 
Unbinding 6 7.10 μs 
CPA Binding 9 4.34 μs 
Unbinding 10 0.97 μs 
HOCPA Binding 8 4.06 μs 
Unbinding 6 2.58 μs 
BnOCPA Binding 7 5.82 μs 
Unbinding 6 4.92 μs 
 
3 Results and Discussion 
3.1 N6-cyclopentyl agonists bind to A1R with similar fashion 
ARs ligands bearing an alkyl ring in N6 (on the adenine scaffold) or C8 (xanthine scaffold) 
position display increased affinity for A1R over A2AR
10. The reason for this is attributed to 
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T2707.35 (A1R) in place of M270
7.35 (A2AR), which shapes a hydrophobic sub-pocket underneath 
ECL3 that partially accommodates the lipophilic substituent. While the inactive structures of 
A1R and A2AR in complex with the xanthine antagonist PSB36
10 have univocally shown this 
structural aspect of the selectivity, no confirmation from crystallography or cryo-EM studies is 
yet available for ARs agonists.  
 Besides reproducing the adenosine cryo-EM binding conformation into A1R (Figure S2, 
Video S1)9, our simulations sampled the orthosteric binding mode of NECA observed on A2AR 
(Figure S2, Video S2)47. In light of this reliability, we propose the likely binding mode of CPA, 
HOCPA, and BnOCPA (Figure 2, Videos S3-S4). As expected, the adenine ring forms a 
bidentate hydrogen bond with N2546.55 and a π- π stacking with F171ECL2, while the N6-
cyclopentyl ring inserts in the hydrophobic pocket under ECL3, interacting with T2707.35 and 
L2536.54 (Figure 2). Mutagenesis experiments confirmed the importance of L2536.53 (Table 2) for 
the affinity of the agonists. BnOCPA is proposed to bind to A1R with same features of the 
smaller ligands CPA and HOCPA (Figure 2b, Video S4). However, during the simulations the 
oxybenzyl group showed25 high flexibility and explored three different orientations (Figure 2b). 
In two of these conformations, BnOCPA interacted with A1R residue L258
6.59 (mode B, Figure 
2b) and Y2717.36 (mode C, Figure 2b). Binding assays with mutants L2586.59A, F2586.59A, 
F2586.59T and Y2717.36A (Table 2) confirmed that these two residues are likely involved in the 
orthosteric complex with BnOCPA. However, a role during agonist association and dissociation 
events cannot be ruled out, as also the affinity for CPA and HOCPA (which are not involved in 
contacts with L2586.59 and Y2717.36 in the bound state, Figure 2a) was affected (Table 2). 
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Figure 2. Binding modes of the agonists according to SuMD path sampling simulations. a) CPA
(magenta) and HOCPA (pink) engage A1R with the same orientation as adenosine (tan stick); the N6-
cyclopentyl group interacts with L2536.54 and T2576.58. b) BnOCPA orients the oxybenzyl group in three
different orientations. Hydrogen bonds with N254ECL2 are shown as dashed lines, while hydrophobic
contacts are depicted as cyan transparent surfaces. 
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3.2 Simulations suggest the binding and unbinding paths of A1R agonists  
SuMD and SuMD path sampling delivered detailed insights on the possible transitory 
metastable states that the agonists experienced along the route to, and from, the orthosteric site 
(Figure 3, Table S1-S4, Figure S4, Figure S5; Video S1-S4). While the endogenous agonist 
adenosine reached the orthosteric site with very limited intermediate interactions with ECL2 
(Figure 3b, Table S1, Figure S4, Video S1), the other ligands formed contacts with this 
extracellular vestibule, with CPA and BnOCPA most involved in metastable states (Figure 3d,h, 
Table S1, Figure S4, Video S3, Video S4). As a general view, the increase in lipophilicity at the 
N6 position (CPA, HOCPA and BnOCPA, Figure 3d,f,h, Table S1, Figure S4) and 5’ position 
(NECA, Figure 3, Figure S3a, Table S1, Figure S4) favored intermediate interactions with ECL2. 
The importance of ECL2 for the binding of NECA, CPA and the antagonist DPCPX to A1R has 
been recently demonstrated12,48. Our simulations suggest I175ECL2 and E172ECL2 as involved in 
interactions during both the binding and unbinding (Figure 3d, Figure S3, Figure S5), while 
E170ECL2, I167ECL2, N159ECL2, and W156ECL2 engaged NECA during the binding (Figure S3a, 
Figure S5). L149ECL2, on the other hand, was not involved in direct interactions with the ligands, 
suggesting an important role in stabilizing the overall secondary structure of ECL2 due to its 
position at the base of the loop helix. Besides the aforementioned residues, further A1R side 
chains were involved along the simulated binding paths for all the agonists considered (Table S1, 
Table S2 Figure S4).  
 SuMD unbinding routes (Figure 3c,e,g,I, Video S1-S4) had only limited overlap with the 
binding routes (Figure 3b,d,f,h, Video S1-S4). The agonists, indeed, established frequent 
interactions with the top of TM1, TM2, and TM7 (Figure 3c,e,g,i, Figure S3b, Table S2, Table 
S4, Figure S5). However, in analogy with the binding simulations, CPA, HOCPA, and BnOCPA 
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(all bearing an N6 hydrophobic moiety) showed a major involvement of ECL2 (Table S3, Table 
S4, Figure S5; Video S3-S4). Many of the A1R residues involved in both agonist association 
(Table S1, Table S2, Figure S4) and dissociation (Table S3, Table S4, Figure S5) are part of the 
orthosteric site. It is therefore not surprising that mutagenesis experiments already pointed out 
their importance12,49–53.  
 Interestingly, our unbiased nonequilibrium simulations pointed out several residues, 
located outside the orthosteric site, involved along the binding and unbinding routes. These 
residues comprise F81.31, Q91.32, Y121.35, I692.64, N702.64, N148ECL2, I175ECL2, L2536.54, T2576.58, 
L2586.59, H264ECL3, K265ECL2, S2677.32, Y2717.36 (Figure 3a). Mutagenesis experiments were 
designed and performed to confirm computational predictions (Figure 3, Table 2, Table S5).  
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Figure 3. Simulated binding and unbinding paths of the agonists and the relative position of the 
A1R mutants tested. a) Two side views of the A1R (white transparent ribbon); residues considered for 
the mutations (Table 2) are shown as grey sticks. The cryo-EM bound adenosine (tan stick) is reported as 
reference. b) to i) Left-hand panels, position of the agonist centroid during simulations, colored according 
to the interaction energy with A1R (white ribbon); residues mutated (Table 2) are shown as sticks and 
colored according to effect on the affinity (red: decreased affinity; green: increased affinity; black: 
unaltered affinity). Right-hand panels, A1R-agonist contacts plotted onto the protein surface and colored 
according to the contacts occupancy. b) Adenosine binding simulations; c) adenosine unbinding 
simulations; d) CPA binding simulations; e) CPA unbinding simulations; f) HOCPA binding simulations; 
g) HOCPA unbinding simulations; h) BnOCPA binding simulations; i) BnOCPA unbinding simulations. 
3.3 Mutagenesis experiments reveal novel A1R residues involved in the binding of 
agonists 
3.3.1 Surface expression of the A1R alanine mutants and CA200645 Kd  
The cell-surface expression of WT and mutant A1R, as determined by mean fluorescence 
intensity of APC (%WT), was comparable to WT for Y121.35A, N702.64A, T2576.58A, L2586.59A, 
K265ECL2A, S2677.32A, L2536.54T and L254F A1R. When compared to WT, the cell-surface 
expression was determined to be significantly reduced for F8A, Q91.32A, N148ECL2A, I175ECL2A, 
H264ECL2A and L2536.54G whereas it was significantly increased for I692.65A, L2536.54A and 
Y2717.36A. This enhanced or reduced mutant A1R cell-surface expression did not correlate with 
changes in CA200645 equilibrium dissociation constant (Kd). For example, the Kd for 
CA200645 determined in L2536.54T was significantly increased when compared to WT but 
showed comparable cell-surface expression. I175 ECL2A and L2536.54G also showed an increased 
Kd but had a reduced cell-surface expression when compared to WT. 
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Importantly, the determined changes in CPA, BnOCPA, HOCPA or adenosine affinity (pKi) 
were determined to be independent of changes in cell-surface expression. For example, despite 
the significantly elevated cell-surface expression of Y2717.36A, the determined compound 
affinity of all four tested compounds was significantly reduced when compared to that 
determined at WT. This is likely due to the high receptor expression in our system and/or 
reserve. The only exception was L2536.54G whereby compound pKi could not be determined due 
to the likely combined effect of low cell-surface expression and reduced CA200645 affinity.  
3.3.2 General effects of alanine substitutions on agonists affinity 
A number of mutations enhanced affinity, while other either decreased affinity or had no 
overall effect. The mutated residues can be divided into three groups according to their positions 
relative to the (un)binding paths sampled during the simulations. 
3.3.3 TM1, TM2 and TM7 residues 
The A1R residues located at the top of TM1, TM2 and TM7 (Figure 3a) were generally 
involved during both the simulated binding (Figure 3b,d,f,h, Figure S4, Figure S5) and unbinding 
(Figure 3c,e,g,i, Figure S4, Figure S5). Adenosine, CPA, and HOCPA displayed decreased 
affinity to A1R mutants Q9
1.32A and Y121.35A (Table 2) and enhanced the binding to F81.31A 
compared to the WT, in agreement with the transitory interactions formed with TM1 during 
simulations (Figure 3b-g, Table S1-S4, Figure S4, Figure S5). The affinity for the agonists 
diminished on Q91.32A and Y121.35A, but BnOCPA was not significantly affected by F81.31A. 
This is apparently in disagreement with simulations, which proposed BnOCPA as the agonist 
more prone to form metastable states in the proximity of F1.318 during the dissociation from the 
receptor (Figure 3i). However, the fact that BnOCPA was the ligand most prone to interact with 
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F8 also during the association (Figure 3h) may suggest a degree of compensation between 
binding and unbinding. That is, the variation of the binding rate can be compensated by an 
opposite change in the unbinding rate (and vice versa) resulting in unchanged affinity. This could 
also be the case of N702.65A, which did not alter the affinity of the agonists, except for BnOCPA 
(Table 2). Binding and unbinding simulations suggested that N702.65 forms numerous 
interactions with the ligands (Table S1-S4, Figure S4, Figure S5). The adjacent residue I692.64, 
instead, when mutated to alanine (I692.64A) significantly decreased the affinity of all the agonists 
(Table 2). Besides being involved in frequent interactions with the agonists (Table S1-S4), I692.64 
is packed in hydrophobic contacts with TM3, possibly stabilizing the neighboring part of ECL2. 
Moving to TM7, the agonists NECA, CPA, HOCPA, and BnOCPA, but not adenosine, 
displayed diminished binding to the S2677.32A (Table 2, Table S5), while all of them lost affinity 
to Y2717.36A (Table2, Table S5). The bulky Y2717.36 side chain, which occupies an important 
position at the interface between the orthosteric site and the extracellular vestibule, could 
participate in numerous intermediate interactions along the (un)binding routes.  
3.3.4 TM6 residues 
The three A1R residues mutated on TM6 (L253
6.54, T2576.58, and L2586.59, Figure 3a) are part 
of different protein environments. L2536.54 shapes part of the hydrophobic pocket underneath 
ECL3 partially responsible for A1/A2A ligands selectivity (along with L269
7.34 and T2707.35). All 
the agonists displayed diminished affinity to L2536.54A (Table 2), with the N6-substituted 
agonists CPA, HOCPA, and BnOCPA most affected, in line with the hydrophobic interactions 
occurring in the bound state (Figure 2). Interestingly, T2576.58A increased the affinity of CPA, 
HOCPA, and BnOCPA. This could be due to an increase in lipophilicity of the protein 
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environment surrounding the cyclopentyl group either in the bound complex or along the 
unbinding pathways, (Figure 3e,g,i). NECA showed reduced affinity to T257A (Table S5, Figure 
S3), confirming the importance of hydrophobic N6-substituents for interactions with the top of 
TM6. L2586.59, which is located at the interface with the membrane, is one of the TM5 and TM6 
residues shaping a saddle between ECL2 and ECL3, where agonists tended to form metastable 
interactions along the simulated (un)binding paths (Figure 3b-i, Figure S4, Figure S5). All the 
agonists (excepted adenosine) displayed a reduced affinity for L2586.59A and L2586.59T , 
suggesting that the bulkier ligands may be more prone to interact with this part of A1R (BnOCPA 
was the only ligand proposed to interact at some extent with L2586.59 in mode B, Figure 2b). The 
affinity decrease (Table 2) displayed by HOCPA and BnOCPA for L2586.59F likely excludes a 
destabilization of the neighbor protein structure, as residue F2586.59 WT A2AR does not change 
the conformation of the top of TM6. 
3.3.5 ECL2 and ECL3 residues 
As I175ECL2 formed numerous interactions with the agonists during the simulations (Figure 3b-
i, Table S1, Table S2, Figure S4, Figure S5), not surprisingly the I175ECL2A mutation reduced the 
affinity of all the ligands (Table 2, Table S5). I175ECL2 could contribute to keeping the aromatic 
side chain of F171ECL2 in an appropriate conformation for interacting with the ligands’ adenine 
ring in the orthosteric complex (Figure S1). On the other hand, N148ECL2A did not affect the 
affinity of the agonists, despite the frequent interactions during the binding simulations (Table 2, 
Figure 3b,d,f,h, Table S1, Table S2, Figure S4, Figure S5). 
While H264ECL2A showed diminished affinity (Table 2) for CPA and BnOCPA (which have 
the most lipophilic N6-group, Figure 1), none of the tested ligands were significantly affected by 
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K265ECL2A. As K265ECL2 is part of a stable salt bridge with E172ECL2, K265ECL2A is expected to 
affect the affinity of the ligands due to the reduced hindrance of the orthosteric site. The subtype 
A2AR bears A265
ECL2 in place of K265ECL2 and the residue involved in the salt bridge with 
E169ECL2 (corresponding to E172ECL2 in A1R) is H264
ECL2. The A2AR H264
ECL2A mutant does 
not display a modified affinity for the antagonists ZM241385, despite the increase in off rate54. 
This could indicate a kinetic compensation due to a faster binding to H264ECL2A (A2AR) and 
K265ECL2A (A1R). A less bulky alanine side chain, indeed, would favor ligand binding and the 
unbinding to a similar extent. 
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Table 2. NanoBRET saturation- and competition-binding assays in WT and mutant Nluc-A1R. CA200645 equilibrium dissociation constant (Kd) and 
compound affinity (pKi) at WT and mutant Nluc-A1R, as determined by NanoBRET saturation and competition ligand-binding assays, respectively.   
     pKi
c 
 Cell-surface expressiona n Kd
b n CPA n BnOCPA n HOCPA n Adenosine n 
WT 100 ±<0.1 8 68.58 ±7.5 5 6.95 ±0.02 3 6.21 ±0.04 4 6.37 ±0.03 4 5.90 ±0.08 4 
F8A 53 ±12.4** 3 90.7 ±21.5 3 7.34 ±0.08* 4 6.37 ±0.02 3 6.95 ±0.07** 3 6.55 ±0.17*** 3 
Q9A 21 ±2.2**** 3 60.6  ±5.4 3 6.41 ±0.09** 3 5.44 ±0.06**** 3 5.71 ±0.05*** 3 5.07 ±0.11**** 3 
Y12A 120 ±19.3 3 75.8 ±6.0 3 6.50 ±0.06** 4 5.44 ±0.06**** 4 5.78 ±0.10*** 4 5.35 ±0.05*** 4 
I69A 158 ±6.9*** 3 147.2 ±13.4* 3 4.94 ±0.06**** 3 4.72 ±0.04**** 3 4.34 ±0.11**** 3 4.64 ±0.13**** 3 
N70A 86 ±9.0 3 51.6 ±3.7 3 6.97 ±0.12 3 5.92 ±0.06* 3 6.05 ±0.09 3 5.83 ±0.05 3 
N148A 13 ±1.2**** 3 70.7 ±13.2 3 7.20 ±0.13 3 6.15 ±0.03 3 6.15 ±0.05 4 5.71 ±0.07 3 
I175A 23 ±2.5 **** 3 153.2 ±27.6** 3 6.30 ±0.06**** 3 5.60 ±0.05**** 3 5.66 ±0.02**** 4 4.91 ±0.11**** 2 
T257A 114 ±19.3 4 128.8 ±16.0 3 7.30 ±0.03** 3 6.77 ±0.05**** 4 6.94 ±0.05**** 3 5.85 ±0.09 3 
L253A 160 ±24.1*** 3 104.1 ±19.3 3 6.17 ±0.06**** 4 5.39 ±0.10**** 4 5.49 ±0.13**** 3 5.40 ±0.06** 3 
L258A 82 ±1.7 3 118.3 ±20.6 3 6.34 ±0.07**** 6 6.03 ±0.05*** 5 5.85 ±0.08**** 5 5.66 ±0.08 5 
H264A 21 ±5.7**** 3 84.1 ±4.6 3 6.33 ±0.09*** 3 5.60 ±0.01**** 3 6.02 ±0.18 3 6.21 ±0.05 3 
K265A 68 ±13.2 3 54.7 ±8.6 3 6.59 ±0.13 3 6.21 ±0.05 4 6.01 ±0.12 4 5.58 ±0.09 3 
S267A 90 ±6.3 3 89.9 ±11.7 3 6.66 ±0.06* 3 5.85 ±0.01*** 3 5.99 ±0.05*** 3 5.66 ±0.08 3 
Y271A 171 ±10.1**** 3 94.4 ±11.1 3 5.82 ±0.03**** 3 5.14 ±0.07**** 4 5.15 ±0.07**** 3 5.13 ±0.07*** 2 
L253T 77 ±17.6 3 200.4 ±24.6**** 3 6.39 ±0.07 3 5.69 ±0.04*** 4 5.69 ±0.04**** 4 -  
.
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L253F 131 ±2.4 4 123.0 ±17.3 3 6.40 ±0.10 3 6.12 ±0.05**** 3 5.79 ±0.08*** 3 -  
L253G 15 ±3.5**** 3 143.3 ±37.5* 3 -  -  -  -  
a Mean fluorescence intensity of APC (% Wild-type (WT)).  Cell-surface expression of WT or mutant Nluc-A1R in HEK 293 cells was determined by flow 
cytometry. Cells were incubated with anti-Nluc antibody followed by APC-conjugated anti-rabbit IgG secondary antibody and the fluorescence detector FL4 
(Em. λ 675/25 nm) used to detect APC fluorescence. 
b CA200645 equilibrium dissociation constant (Kd) as determined by NanoBRET saturation binding assays. 
c Compound affinity (pKi) (mean ± SEM) determined through NanoBRET competition-binding assays in WT/mutant Nluc-A1R stably expressing HEK 293 
cells. The resulting concentration-dependent decrease in BRET ratio at 10 minutes was used to calculate pKi. Compound affinity could not be determined (-) 
for L253G Nluc-A1R given the low cell-surface expression and reduced binding affinity of CA200645 (Kd).  
Data are expressed as mean ± SEM obtained in n separate experiments. All individual experiments were conducted in duplicate. Statistical significance (*, p< 
0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001) compared to WT was determined by one-way ANOVA with Dunnett’s post-test. 
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3.4 Towards the definition of the structure-binding/unbinding path relationships of A1R 
agonists. 
The (un)binding kinetics have a major impact on both pharmacodynamics55–57 and 
pharmacokinetics58 of a drug. Even small structural modifications within a congeneric series of 
ligands modify the kinetics through modified on and off rates59. The reason for this lies in the 
enormously higher number of different intermediate states that a ligand can experience along 
(un)binding paths compared to the orthosteric complexes, where it is restrained by 
intermolecular interactions and steric hindrances. Protein-ligand recognition events have very 
complex energy landscapes60–63 and small changes in either the structure of the ligand or the 
protein can alter the nature and the position of the transition states along the (un)binding routes64. 
To investigate this aspect on the A1R agonists, we compared the A1R interaction patterns 
between adenosine, CPA or BnOCPA (Figure 4) to understand how the introduction of the N-6 
cyclopentyl group on the adenosine scaffold and the introduction of the oxybenzyl group on CPA 
(BnOCPA) could alter the overall (un)binding mechanisms. 
3.4.1 Introduction of the N6-cycloalkyl ring on the adenosine scaffold.  
In general, CPA formed more intermediate interactions than adenosine with the extracellular 
vestibule of A1R (Figure 4a,b). The presence of the N6-cycloalkyl substituent produced mode 
contacts with ECL2 and residues located at the top of TM1, TM5, TM6, TM7, and ECL3 (Figure 
4a,b). This scenario is in good agreement with mutagenesis experiments (Table 2) showing CPA 
affinity (but not adenosine’s affinity) was significantly affected by T2576.58A, L2586.59A, 
H264ECL3A, and S2677.32A, all located in the proximity of the extracellular vestibule. 
3.4.2 Introduction of the 2-oxybenzyl group on CPA N6-cycloalkyl ring.  
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The presence of this lipophilic moiety (BnOCPA was the bulkier ligand considered) favored 
more interactions with the top of TM5 and TM6 during association (Figure 4c) and with the top 
of TM1 and TM2 during dissociation (Figure 4d). CPA, on the other hand, was more prone to 
interact with the ECL2 (Figure 4c,d). The changes in the barycenter of the contacts during 
unbinding due to the 2-oxybenzyl group could explain the unique profile that BnOCPA showed 
on A1R mutants F8
1.31A and N702.65A (Table 2). BnOCPA, indeed, was the only agonist 
significantly affected by N702.65A, and the only one not affected by F81.31A. 
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Figure 4. Structural modification of A1R agonists led to different simulated binding and unbinding 
mechanisms. a) and b) Heatmap showing the contact difference, during SuMD path sampling, between 
adenosine and CPA, which differ for the N6-cyclipentyl group (highlighted as a dashed circle line); A1R 
blue surfaces indicates more contacts formed with adenosine, while red surfaces are indicative of more 
contacts with CPA. a) Binding simulations; b) Unbinding simulations. c) and d) Heatmap showing the 
contacts difference, during SuMD path sampling, between CPA and BnOCPA, which differ for the 
oxybenzyl group (highlighted as a dashed circle line); A1R blue surfaces indicate more contacts formed 
with CPA, while red surfaces are indicative of more contacts with BnOCPA c) Binding simulations; d) 
Unbinding simulations.  
 
4. Conclusion 
In the present work, unbiased nonequilibrium MD simulations and mutagenesis experiments 
were combined to study the dynamic binding and unbinding of A1R agonists. The in silico 
analysis suggested several involved A1R residues on regions so far poorly investigated
65. 
Mutagenesis experiments generally confirmed the computational prediction and allow mapping 
novel receptor spots involved in the association or dissociation of the selective agonists.  
 The importance of intermediate metastable states along the (un)binding paths in 
modulating the overall affinity of ARs agonist is gradually emerging12,66. For the binding, our 
results indicated that A1R ECL2 is involved in numerous preliminary contacts, as well as the top 
of TM6, TM1, TM2 and TM7. The dissociation from A1R follows similar routes, but ECL2 is 
generally less engaged (especially by the more hydrophilic adenosine and NECA). The chemical 
modifications that increase the agonists’ selectivity towards A1R (e.g. the introduction of N6-
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cycloalkyl groups) also change the (un)binding mechanism, favoring the interactions with the 
extracellular vestibules in general, and the hydrophobic allosteric pocket located on ECL2 in 
particular.  
 GPCR-ligand complexes form and dissociate through multistep mechanisms. MD 
simulations and mutagenesis experiments are frequently combined to deliver structural insights 
on endpoint protein-ligand complexes. To the best of our knowledge67–69 this is the first that the 
whole process of formation/dissociation of several GPCR ligands is reconstructed with a 
combined in silico and in vitro approach. Our results pave the way to the rationalization of 
structure-kinetic relationship (SKR) for A1R, with potential repercussion on the rational design 
of long-awaited clinical agents. 
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